Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma

卡培他滨 医学 奥沙利铂 围手术期 内科学 新辅助治疗 临床终点 不利影响 腺癌 胃肠病学 人口 实体瘤疗效评价标准 肿瘤科 临床研究阶段 化疗 外科 临床试验 癌症 结直肠癌 环境卫生 乳腺癌
作者
Jiaxing He,Bo Zhang,Shuai Zhou,Ying Yang,Zhuo Han,Tao Wu,Qing Qiao,Haicheng Yang,Xianli He,Nan Wang
出处
期刊:Cancer Science [Wiley]
标识
DOI:10.1111/cas.16425
摘要

Abstract Immune checkpoint inhibitors combined with chemotherapy have shown promising efficacy in treating gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the neoadjuvant setting. This phase II trial (NCT05715632) aimed to investigate the efficacy and safety of perioperative camrelizumab plus XELOX in patients with locally advanced G/GEJ adenocarcinoma. Treatment‐naive patients with cT3‐4aN1‐3 M0 resectable locally advanced G/GEJ adenocarcinoma were recruited to receive camrelizumab (200 mg, intravenously) on Day 1 combined with XELOX (oxaliplatin at 130 mg/m 2 on Day 1 and capecitabine at 1000 mg/m 2 on Days 1–14) every 3 weeks for four cycles, followed by surgery and adjuvant camrelizumab combined with XELOX every 3 weeks for four cycles. The primary endpoint was the pathological complete response (pCR; ypT0N0) rate. From September 2020 to January 2023, 46 patients were enrolled, and all patients completed neoadjuvant therapy. Among them, 43 underwent D2 resection. In the intention‐to‐treat population, pCR was achieved in nine patients (19.6%, 95% confidence interval [CI]: 9.9%–34.4%), and the major pathological response was achieved in 25 patients (54.3%, 95% CI: 39.2%–68.8%). The objective response rate was 69.6%, of which 12 patients achieved a complete response and 20 patients achieved a partial response. The 1‐year event‐free survival and disease‐free survival rates were both 93.1%. Treatment‐related adverse events (TRAEs) occurred in 42 (91.3%) patients, and grade 3 TRAEs occurred in nine (19.6%) patients. No grades 4–5 TRAEs were observed. Perioperative camrelizumab combined with XELOX showed promising pathological response with an acceptable safety profile in patients with resectable locally advanced G/GEJ adenocarcinoma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Luu完成签到 ,获得积分10
1秒前
1秒前
2秒前
灵魂发布了新的文献求助10
3秒前
高挑的若剑完成签到,获得积分10
4秒前
mt13完成签到,获得积分10
4秒前
科研通AI2S应助科研通管家采纳,获得10
5秒前
yar应助科研通管家采纳,获得10
5秒前
田様应助科研通管家采纳,获得10
5秒前
科研通AI5应助科研通管家采纳,获得10
5秒前
共享精神应助科研通管家采纳,获得10
5秒前
5秒前
Owen应助科研通管家采纳,获得10
5秒前
5秒前
yar应助科研通管家采纳,获得10
5秒前
ll应助科研通管家采纳,获得10
5秒前
ll应助科研通管家采纳,获得10
5秒前
byebyettt完成签到 ,获得积分10
6秒前
量子星尘发布了新的文献求助10
6秒前
7秒前
情怀应助wukang采纳,获得10
9秒前
科目三应助lei029采纳,获得10
11秒前
旧辞完成签到,获得积分10
12秒前
冰凉完成签到,获得积分10
14秒前
木子完成签到,获得积分10
15秒前
17秒前
19秒前
悠悠我心完成签到,获得积分20
19秒前
wukang给wukang的求助进行了留言
20秒前
大个应助风中无血采纳,获得10
23秒前
人生如梦应助追寻天亦采纳,获得10
23秒前
26秒前
李健的小迷弟应助N_N采纳,获得10
28秒前
苏航发布了新的文献求助10
29秒前
30秒前
风中无血发布了新的文献求助10
34秒前
昏睡的绍辉完成签到,获得积分10
36秒前
37秒前
搜集达人应助daxiong采纳,获得10
40秒前
量子星尘发布了新的文献求助10
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975378
求助须知:如何正确求助?哪些是违规求助? 3519775
关于积分的说明 11199621
捐赠科研通 3256067
什么是DOI,文献DOI怎么找? 1798124
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305